Aquestive Therapeutics Inc. Stock Prediction and Forecast [AQST]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 27 Sept 2025, 03:21 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Aquestive Therapeutics Inc. Stock Prediction and Forecast [AQST]](https://i.ytimg.com/vi/a8maFTJWtTM/hqdefault.jpg)
AI-generated source summary
The analysis focuses on Aquestive Therapeutics (AQST), highlighting its recent strong buy candidate rating with a score of 6.94. The stock has shown an impressive gain of nearly 20% since its initial categorization, equating to approximately 1.3% per day. The stock is showing a short-term upward trend, with potential support at $5.79. According to fan theory, the potential peak level could be $7.01. The 3-month trend suggests a potential change of approximately 36.98%, with a return ranging between 4.60% and 32.46%. For the last trading day, the stock closed at $5.99, which is +13.88%. Trading volume is increasing along with the price and the stock showed an average daily volatility of 8.74% and a very high risk. Insider trading power is positive at 63.503, while analyst ratings show a general sell advice. The P/E ratio is negative, and it may open higher by approximately 8.3 cents and start trading at $6.07.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.